Setterwalls is assisting the owners in connection with the divestment of the biotech company Mabtech to IK Small Cap II Fund.
Mabtech is a Swedish biotech company founded in 1986. The company develops and produces a broad spectrum of monoclonal antibodies for ELISpot, FluoroSpot and ELI-SA. The products are mainly used by scientists around the world to study immune responses in e.g. infectious diseases, cancer and allergies and are used as monitoring tools in vaccine trials. Since last year, Mabtech also manufactures and sells the product “IRIS”, which is a 4-color FluoroSpot and ELISpot reader with an entirely new algorithm that ensures reliable multiplexing. The three founders and members of management will continue to invest in the company and be part of the journey going forward. The deal is expected to be completed in mid-December 2019.